Mineralocorticoid effects due to cortisol inactivation overload explain the beneficial use of hydrocortisone in septic shock

Medical Hypotheses

Volumn 70, Issue 1, 2008, Pages 56-60

  Druce, L A ^a   Thorpe, C M ^a   Wilton, A ^a  

^a YSBYTY GWYNEDD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; BETAMETHASONE; CARBENOXOLONE; DEXAMETHASONE; FLUDROCORTISONE; HYDROCORTISONE; METHYLPREDNISOLONE; MINERALOCORTICOID; PREDNISOLONE;

ARTICLE; CATECHOLAMINE RELEASE; CUSHING DISEASE; DRUG MECHANISM; DRUG POTENCY; GLYCYRRHIZA; HUMAN; IMMUNE RESPONSE; METABOLIC ACIDOSIS; METABOLIC ALKALOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPTIC SHOCK; VASCULAR RESISTANCE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; CUSHING SYNDROME; GLYCYRRHIZA; HUMANS; HYDROCORTISONE; MINERALOCORTICOIDS; MODELS, BIOLOGICAL; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID; SHOCK, SEPTIC;

EID: 36448989747     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.04.031     Document Type: Article

References (45)

1. Wenzel R.P. Treating sepsis. N Eng J Med 347 (2002) 966-967
2. Cooperative Study Group. The effectiveness of hydrocortisone in the management of severe infections. JAMA 183 (1963) 462-465
3. Lefering R., and Neugebauer E. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 23 (1995) 1294-1303
4. Cronin L., Cook D.J., Carlet J., et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 23 (1995) 1430-1439
5. Sessler C.N. Steroids for septic shock back from the dead. Chest 123 (2003) 482s-489s
6. Minneci P.C., Deans K.J., Banks S.M., Eichacker P.Q., and Natanson M.D. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Int Med 141 (2004) 47-56
7. Annane D., Bellissant E., Bollaert P.E., Briegel J., Keh D., and Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ 329 (2004) 480-489
8. Funder J.W. Mineralocorticoid receptors and glucocorticoid receptors. Clin Endocrinol 45 (1996) 651-656
9. Arriza J.L., Weinberger C., Cerelli G., et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with glucocorticoid receptors. Science 237 (1987) 268-275
10. James V. Hydroxysteroid dehydrogenases as hormonal regulators. Clin Endocrinol 45 (1996) 613-614
11. Seckl J.R., and Chapman K.E. The 11β-hydroxysteroid dehydrogenase system, a determinant of glucocorticoid and mineralocorticoid action. Eur J Biochem 249 (1997) 361-364
12. Tomlinson J.W., Walker E.A., Bujalska I.J., et al. 11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response. Endocr Rev 25 (2004) 831-866
13. Stewart P.M., Murry B.A., and Mason J.I. Human kidney 11β-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. J Clin Endocrinol Metab 79 (1994) 480-484
14. Albiston A., Obeyesekere V., Smith R., and Krozowski Z.S. Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 105 (1994) R11-R17
15. Edwards C.R.W., Stewart P.M., Burt D., et al. Localisation of 11β-hydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor. Lancet ii (1988) 986-989
16. Funder J.W., Pearce P.T., Smith R., and Smith A.I. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242 (1988) 583-585
17. Bollaert P.E., Charpentier C., Levy B., Debouverie M., Audibert G., and Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 26 (1998) 645-650
18. Briegel J., Forst H., Haller M., et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomised, double-blinded, single center study. Crit Care Med 27 (1999) 723-732
19. Chawla K., Kupfer Y., Goldman I., et al. Hydrocortisone reverses refractory septic shock. Crit Care Med 27 (1999) A33
20. Keh D., Boehnke T., and Weber-Cartens S. Immunologic and haemodynamic effects of "low dose" hydrocortisone in septic shock. Am J Respir Crit Care Med 167 (2003) 512-520
21. Stewart P.M., Walker B.R., Holder G., O'Halloran D., and Shackleton C.H.L. 11β-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotrophin syndrome. J Clin Endocrinol Metab 80 (1995) 3617-3620
22. Mune T., Rogerson F.M., Nikkila H., Agarwal A.K., and White P.C. Human hypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase. Nat Genet 10 (1995) 394-399
23. Wilson R.C., Harbison M.D., and Krozowski Z.S. Several homozygous mutations in the gene for 11β-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 80 (1995) 3145-3150
24. Stewart P.M., Krozowski Z.S., Gupta A., et al. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydrogenase type 2 gene. Lancet 347 (1996) 88-91
25. Stewart P.M., Corrie J.E.T., Shackleton C.H.L., and Edwards C.R.W. Syndrome of apparent mineralocorticoid excess: a defect in the cortisol-cortisone shuttle. J Clin Invest 82 (1998) 340-349
26. Farese R.V., Biglieri E.G., Shackleton C.H.L., Irony I., and Gomez-Fontes R. Liquorice induced hypermineralocorticoidism. New Engl J Med 325 (1991) 1225-1227
27. Stewart P.M., Wallace A.M., Valentino R., Burt D., Shackleton C.H.L., and Edwards C.R.W. Mineralocorticoid activity of liquorice: 11β-hydroxysteroid dehydrogenase deficiency comes of age. Lancet ii (1987) 821-824
28. Ulick S., Wang J.Z., Blumenfeld J.D., and Pickering T.G. Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 74 (1992) 963-967
29. Palermo M., Shackleton C.H.L., Mantero F., and Stewart P.M. Urinary free cortisone and the assessment of 11β-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol 45 (1996) 605-664
30. Chobanian A.V., Volicer L., Tifft C.P., Gavras H., Liang C., and Faxon D. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. New Engl J Med 301 (1979) 68-73
31. Annane D., Bellisant E., Sebille V., et al. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Brit J Clin Pharmacol 46 (1998) 589-597
32. Klastersky J., Cappel R., and Debusscher L. Effectiveness of betamethasone in management of severe infections. New Engl J Med 284 (1971) 1248-1250
33. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg 184 (1976) 333-341
34. Lucas J.M., and Ledgerwood A. The cardiopulmonary response to massive doses of steroids in patients with septic shock. Arch Surg 119 (1984) 537-541
35. Thompson W.L., Gurley H., Lutz B., et al. Inefficacy of corticosteroids in shock. Clin Res 24 (1976) 258A
36. Sprung C.L., Caralis P.V., Marcial E.H., et al. The effect of high dose corticosteroids in patients with septic shock: a prospective, controlled trial. New Engl J Med 311 (1984) 1137-1143
37. Bone R.C., Fisher C.J., Clemmer T.P., et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Eng J Med 317 (1987) 653-658
38. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. New Engl J Med 317 (1987) 659-665
39. Luce J.M., Montgomery A.B., Marks J.D., et al. Ineffectiveness of high dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 138 (1998) 62-68
40. Rogers J. Large doses of steroids in septicaemic shock. Brit J Urol 42 (1970) 742
41. Annane D., Sebille V., Charpentier G., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288 (2002) 862-871
42. Yildiz O., Doganay M., Aygen B., Guven M., Kelcutimur E., and Tutum A. Physiologic-dose steroid therapy in sepsis. Crit Care 6 (2002) 251-259
43. Kenyon J.N., and Albertson T.E. Steroids and sepsis: time for another reevaluation. J Intensive Care Med 17 (2002) 68-74
44. Prigent H., Maxime V., and Annane D. Clinical review: corticotherapy in sepsis. Crit Care 8 (2004) 122-129
45. Perla D., and Marnorston J. Suprarenal cortical hormone and salt in the treatment of pneumonia and severe infections. Endocrinology 27 (1940) 367-374